Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.

Hazell P.

Australas Psychiatry. 2010 Dec;18(6):556-9. doi: 10.3109/10398562.2010.498049. Review.

PMID:
21117844
[PubMed - indexed for MEDLINE]
2.

A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder.

Connor DF, Steeber J, McBurnett K.

J Dev Behav Pediatr. 2010 Jun;31(5):427-40. doi: 10.1097/DBP.0b013e3181e121bd. Review.

PMID:
20535081
[PubMed - indexed for MEDLINE]
3.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
[PubMed - indexed for MEDLINE]
4.

The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder.

Serra-Pinheiro MA, Mattos P, Souza I, Pastura G, Gomes F.

Arq Neuropsiquiatr. 2004 Jun;62(2B):399-402. Epub 2004 Jul 20.

PMID:
15273834
[PubMed - indexed for MEDLINE]
Free Article
5.

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.

J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):240-8.

PMID:
15725968
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Wigal SB.

CNS Drugs. 2009;23 Suppl 1:21-31. doi: 10.2165/00023210-200923000-00004. Review.

PMID:
19621975
[PubMed - indexed for MEDLINE]
7.

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.

Hazell P, Zhang S, WolaƄczyk T, Barton J, Johnson M, Zuddas A, Danckaerts M, Ladikos A, Benn D, Yoran-Hegesh R, Zeiner P, Michelson D.

Eur Child Adolesc Psychiatry. 2006 Mar;15(2):105-10.

PMID:
16523251
[PubMed - indexed for MEDLINE]
8.

Does oppositional defiant disorder have temperament and psychopathological profiles independent of attention deficit/hyperactivity disorder?

Kim HW, Cho SC, Kim BN, Kim JW, Shin MS, Yeo JY.

Compr Psychiatry. 2010 Jul-Aug;51(4):412-8. doi: 10.1016/j.comppsych.2009.09.002. Epub 2009 Dec 21.

PMID:
20579516
[PubMed - indexed for MEDLINE]
9.

Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.

Aman MG, Binder C, Turgay A.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):243-54.

PMID:
15319021
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.

Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.

J Atten Disord. 2004 Oct;8(2):45-52.

PMID:
15801334
[PubMed - indexed for MEDLINE]
11.

Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study.

Groenman AP, Oosterlaan J, Rommelse N, Franke B, Roeyers H, Oades RD, Sergeant JA, Buitelaar JK, Faraone SV.

Addiction. 2013 Aug;108(8):1503-11. doi: 10.1111/add.12188. Epub 2013 Apr 22.

PMID:
23506232
[PubMed - indexed for MEDLINE]
12.

The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study.

Biederman J, Petty CR, Dolan C, Hughes S, Mick E, Monuteaux MC, Faraone SV.

Psychol Med. 2008 Jul;38(7):1027-36. doi: 10.1017/S0033291707002668. Epub 2008 Jan 21.

PMID:
18205967
[PubMed - indexed for MEDLINE]
13.

[Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].

Wiesegger G, Kienbacher C, Pellegrini E, Scheidinger H, Vesely C, Bangerl W, Friedrich M.

Neuropsychiatr. 2007;21(3):187-206. Review. German.

PMID:
17915180
[PubMed - indexed for MEDLINE]
14.

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW.

Atten Defic Hyperact Disord. 2009 Dec;1(2):201-10. doi: 10.1007/s12402-009-0012-4. Epub 2009 Sep 23.

PMID:
20234828
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Child maltreatment, other trauma exposure, and posttraumatic symptomatology among children with oppositional defiant and attention deficit hyperactivity disorders.

Ford JD, Racusin R, Ellis CG, Daviss WB, Reiser J, Fleischer A, Thomas J.

Child Maltreat. 2000 Aug;5(3):205-17.

PMID:
11232267
[PubMed - indexed for MEDLINE]
16.

The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.

van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM.

Clin Psychol Psychother. 2012 May-Jun;19(3):270-8. doi: 10.1002/cpp.750. Epub 2011 Mar 14.

PMID:
21404369
[PubMed - indexed for MEDLINE]
17.

Neurocognitive function in attention-deficit-hyperactivity disorder with and without comorbid disruptive behaviour disorders.

Barnett R, Maruff P, Vance A.

Aust N Z J Psychiatry. 2009 Aug;43(8):722-30. doi: 10.1080/00048670903001927.

PMID:
19629793
[PubMed - indexed for MEDLINE]
18.

Dysthymic disorder contributes to oppositional defiant behaviour in children with Attention Deficit Hyperactivity Disorder, combined type (ADHD-CT).

Vance A, Sanders M, Arduca Y.

J Affect Disord. 2005 Jun;86(2-3):329-33.

PMID:
15935256
[PubMed - indexed for MEDLINE]
19.

Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.

Pliszka SR.

J Clin Psychiatry. 1998;59 Suppl 7:50-8. Review.

PMID:
9680053
[PubMed - indexed for MEDLINE]
20.

Managing attention deficit/hyperactivity disorder: unmet needs and future directions.

Steer CR.

Arch Dis Child. 2005 Feb;90 Suppl 1:i19-25. Review.

PMID:
15665152
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk